Strategic Investment Positions Company with Approximately $19M in Cash

ENGLEWOOD, CO / ACCESSWIRE / November 30, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of a strategic investment in the company by Armistice Capital (“Armistice”). Armistice has invested $5 million in the form of a three-year senior secured note.

This investment by Armistice has been made in conjunction with the company’s licensing of Tuzistra® XR and a complementary antitussive pending FDA approval and is intended to further support the growth of the company’s commercial portfolio.

Josh Disbrow, Aytu BioScience’s Chief Executive Officer, commented “We thank Armistice Capital and founder Steve Boyd for this commitment to Aytu’s growth in providing this financing. Armistice has an outstanding reputation as a healthcare investor, and we look forward to working with Steve and the Armistice team. We’re excited about Aytu’s growth prospects and the current strength of the company given our product portfolio, cash position, and sequential revenue growth we’ve demonstrated over the last three quarters.”

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund focused primarily on the health care and consumer sectors with approximately $800 million in assets under management. Armistice invests predominantly in equities and seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated investment returns. Steven Boyd, Chief Investment Officer, founded Armistice Capital in 2012. Steven was the first analyst at Senator Investment Group in 2008, joining the firm with its founders from York Capital. Armistice was the winner of 2017 US Hedge Fund Performance Awards by HFM for long/short equity, long/short equity long-term performance (5 years) under $1billion, and single manager long-term performance under $1 billion.

The $5 million senior secured note has a three-year term, carries an 8% coupon, is secured by the revenue streams of Tuzistra XR and the complementary antitussive, and may be repaid by the company at any time 30 days following closing without penalty. Details of the secured note can be found on Form 8-K that will be filed with the U.S. Securities Exchange Commission on or around December 3, 2018.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or “Low T”). Aytu also has exclusive U.S. and Canadian rights to ZolpiMist™, an FDA-approved, commercial-stage prescription sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Aytu recently acquired exclusive U.S. commercial rights to Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. Tuzistra XR is a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an extended-release oral suspension. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside of the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved, Mexican COFEPRAS approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu’s strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as ”may,” ”will,” ”should,” ”forecast,” ”could,” ”expect,” ”suggest,” ”believe,” ”estimate,” ”continue,” ”anticipate,” ”intend,” ”plan,” “prospects” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks relating to gaining market acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ”Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Investors:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Aytu BioScience, Inc.

ReleaseID: 529423

LAS VEGAS, NV / ACCESSWIRE / November 30, 2018 / MJ Harvest, Inc. (OTC PINK: MJHI).

Following a successful MJ BizCon event in Las Vegas, MJHI announces expansion of our distribution network and the development of a number of additional product targets for acquisition and/or distribution.

The Company has now added South American distribution through Horticultura Técnica de Chile S.A. (Hortitec Chile), a leading distributor of horticulture products throughout South America, with presence in Chile, Argentina, Uruguay and Colombia, countries leading a South American wave of commercial cannabis activity.

“We are pleased by the expansion we see coming out of MJ BizCon,” said Patrick Bilton, MJHI CEO. “We are adding new territories and creating new channels. We have a number of solid leads from our attendance at MJ BizCon, and expect to be adding several additional product lines in the near future that will further enhance our product offerings to our Distributors.”

About MJ Harvest: MJ Harvest acquires and markets products and technologies that are designed to benefit growers and processors in the horticultural and agricultural industries. We recently launched ProCannaGro.com to provide a professionally designed and maintained web-based marketing outlet for our product brands and technologies. We are currently building our product lines and distribution channels. Please contact us if you have a product or technology that would benefit from an enhanced marketing program and international distribution channels.

Forward-Looking Statements:

This press release contains forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company assumes no obligation to update any forward-looking statement in order to reflect any event or circumstance that may arise after the date of this release.

CONTACT:

MJ Harvest, Inc.
9205 West Russell Rd., Bldg 3 ST 240
Las Vegas, NV 89148
Telephone: 954.519.3115

Tcktsllc@earthlink.net

@HarvestMJ

SOURCE: MJ Harvest, Inc.

ReleaseID: 529451

HOUSTON, TX / ACCESSWIRE / November 30, 2018 / Camber Energy, Inc. (NYSE American: CEI) (the ”Company” or ”Camber”), based in Houston, Texas, a growth-oriented, independent oil and gas company engaged in the development of crude oil, natural gas and natural gas liquids, announced the execution of a non-binding memorandum of understanding in connection with the contemplated acquisition of an asset located in Greely and Hamilton Counties, Kansas for a purchase price of $4,000,000 in equity. The closing of the transaction is subject to customary closing conditions, negotiation of final transaction documents and transaction terms, and other conditions, and may not close timely, on the terms set forth in the Memorandum of Understanding, or at all. The closing is contemplated to occur in December 2018.

In the event the transaction closes, the Company will acquire working interests which include up to approximately 30,000 net leasehold acres in Greely and Hamilton Counties, Kansas, including 181 non-producing well bores. The acquisition will also include some existing production and the required infrastructure and equipment necessary to support future hydrocarbon production.

Camber is evaluating hydrocarbon production opportunities across all of the to-be acquired acreage including the existing non-producing well bores for workover opportunities. The Company plans to begin the process of reestablishing production from some of the non-producing well bores assuming the closing occurs.

Louis G. Schott, the Interim CEO of Camber noted that, ”We are currently performing due diligence on this opportunity. In the event we are satisfied with our due diligence and close the transaction, this acquisition will provide significant opportunities for the Company to increase its production, cash flows and reserve base. We plan to begin workovers as quickly as possible following a closing with the goal of having production from some of the non-producing well bores restored within a month of closing.”

Mr. Schott continued, ”This is all part of Camber’s plan to add similar low risk acquisitions which can provide an inventory of opportunities to grow the Company through increases in cash flow and reserve base.”

About Camber Energy, Inc.

Based in Houston, Texas, Camber Energy (NYSE American: CEI) is a growth-oriented, independent oil and gas company engaged in the development of crude oil, natural gas and natural gas liquids in the Texas Panhandle as well as other basins. For more information, please visit the Company’s website at www.camber.energy.

Safe Harbor Statement and Disclaimer

This release includes ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations, opinion, belief or forecasts of future events and performance. A statement identified by the use of forward-looking words including ”will,” ”may,” ”expects,” ”projects,” ”anticipates,” ”plans,” ”believes,” ”estimate,” ”should,” and certain of the other foregoing statements may be deemed forward-looking statements. Although Camber believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release. These include risks inherent in natural gas and oil drilling and production activities, including risks of fire, explosion, blowouts, pipe failure, casing collapse, unusual or unexpected formation pressures, environmental hazards, and other operating and production risks, which may temporarily or permanently reduce production or cause initial production or test results to not be indicative of future well performance or delay the timing of sales or completion of drilling operations; delays in receipt of drilling permits; risks with respect to natural gas and oil prices, a material decline which could cause Camber to delay or suspend planned drilling operations or reduce production levels; risks relating to the availability of capital to fund drilling operations that can be adversely affected by adverse drilling results, production declines and declines in natural gas and oil prices; risks relating to unexpected adverse developments in the status of properties; risks relating to the absence or delay in receipt of government approvals or third party consents; risks relating to funding we may never receive pursuant to the November 2018 Stock Purchase Agreement; risks relating to our ability to close the transactions contemplated by the Memorandum of Understanding; and other risks described in Camber’s Annual Report on Form 10-K and other filings with the SEC, available at the SEC’s website at www.sec.gov. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company’s SEC filings are available at http://www.sec.gov.

SOURCE: Camber Energy, Inc.

ReleaseID: 529409

Rutherrin® mediated Photo Dynamic Therapy improves cancer specific immune responses by switching the so called “Don’t eat me” signal that cancer cells use to trick the immune system into the “Eat me” signal on treated human glioblastoma cells, a relevant cell model of Glioblastoma Multiforme.

TORONTO, ON / ACCESSWIRE / November 30, 2018 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, announced today that Theralase’s Rutherrin® Photo Dynamic Therapy (“PDT”) has been shown to increase its efficacy in cancer treatments, inducing a cancer specific immune response, by switching the so-called “Don’t eat me” signal to an “Eat me” signal on treated human glioblastoma cells. This switch in cellular signalling improves the uptake of treated cancer cells by immune cells, such as: Antigen Presenting Cells (“APCs”) (i.e.: macrophages and dendritic cells). APCs are a part of the immune system, with a primary responsibility of destroying foreign cells, such as bacteria and viruses, while also destroying dead and dying cells such as cancer cells, if they are able to detect them.

Rutherrin® PDT’s mechanism of action was evaluated in human glioblastoma cell lines, a relevant cell model of Glioblastoma Multiforme (“GBM”), a deadly form of human brain cancer. As previously disclosed in earlier pre-clinical studies, Rutherrin® mediated PDT had a significant increase in survival over untreated controls and also over Aminolevulinic Acid (“ALA”)-PDT treated rats. It was shown that there was a significant increase in the infiltration of cancer specific CD8+ T cells that kill cancer cells.

To further evaluate the mechanism of CD8+ T cells infiltration, Theralase researchers quantified the effect of Rutherrin® PDT on the so-called “Don’t eat me” versus “Eat me” signalling of cells. Expression of the CD47 molecule on cancer cells protects them from destruction by the immune system and is associated with the “Don’t eat me” signal; thus preserving dangerous cells and inhibiting the immune response. On the other hand, expression of extracellular calreticulin (“CRT”) is associated with the “Eat me” signal; thus, improving cancer cell uptake by APCs, potentiating a cancer specific immune response. Therefore, development of therapeutic strategies that enable downregulation of CD47 expression and up-regulation of CRT signalling is desirable to improve clinical outcomes of cancer patients.

Data obtained in human glioma cell line U87 showed that more than 40% of the dying cells in a Rutherrin® PDT treated group show extra cellular expression of CRT (“Eat me” signal), compared to less than 20% of cells in controls (untreated).

In the same set of experiments, the “Don’t eat me” signals were decreased in Rutherrin® PDT treated cells, showing a 45% decrease in CD47 expression. With an increase in CRT (“Eat me”) signal and a decrease in CD47 (“Don’t eat me”) signal, there is a strong immune response in the destruction of cancer cells versus control.

Manjunatha Ankathatti Munegowda, Ph.D., DVM, MBA, Research Scientist, Theralase stated, “This discovery supports our previous observations that Rutherrin® PDT induces a strong cancer specific immune response post PDT treatment. These results suggest the treatment with Rutherrin® PDT has strong advantages over other therapies; in addition to the primary acute response in killing cancer cells. Rutherrin® PDT is thus able to induce a cancer specific immune response targeting possible GBM recurrences, post PDT treatment.”

Arkady Mandel M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase remarked, “Cancer can often evade the immune system by sending signals that trick the immune system into thinking that the cancer cells are healthy cells and that they should be ignored. One of these tricks involves a cellular signaling pathway that presents a “Don’t eat me” signal to the immune system that tricks the immune system into not engulfing and destroying the cancer cell. We discovered that Rutherrin® PDT overcomes this cellular signalling trick, which will allow APCs to see cancer cells for what they really are and to detect and destroy them. Moreover, the recent experiments have discovered that in addition to suppressing the “Don’t eat me” signal in treated human glioblastoma (brain) cancer cells Tharalase’s anti-cancer PDT technology programs the immune system to seek and destroy cancer cells via upregulation of the “Eat me” signal in PDT treated cancer cells. Using a two-pronged therapeutic approach and targeting both pathways at once could prove very effective in clinical development of Rutherrin® PDT and holds huge potential in the war on brain cancer and on cancer in general.”

About GBM

There are an estimated 24,000 new cases of malignant gliomas diagnosed in the US annually, with more than 14,000 deaths each year. In the majority of cases, patients experience recurrence following initial treatment. This is especially true for GBM, the most common and lethal form of brain cancer. As a result, most patients do not survive beyond two years post diagnosis.

About Theralase Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information is available at www.theralase.com and www.sedar.com.

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding Theralase’s proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of Theralase to: successfully fund and complete Phase I or Phase II GBM clinical studies, secure the requisite regulatory approvals to commence these GBM clinical studies and implement its development plans. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
info@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 529411

This News Release is not for Distribution or Dissemination in the Unites States of America

TORONTO, ON / ACCESSWIRE / November 30th, 2018 / Ubique Minerals Limited (CSE:UBQ) (“Ubique” or “the Company”) is pleased to announce that it has received the assay results from the last holes drilled in 2018 at its Daniel’s Harbour property in western Newfoundland. Results of samples from this final set of six holes, UM 23-18 through UM 28-18, identified high grade zinc intersections in all six holes, with intervals grading up to 16.1% zinc over 0.55 metres in hole UM 23-18. Full results are given below.

Ubique 2018 Drilling Program Results

Drill Hole #

Starting depth (m)

Width (m)

Assay Zn %

UM-23-18

53.95

1.70

5.52

Including

54.50

0.55

16.10

UM-24-18

61.58

1.67

3.22

Including

62.95

0.30

7.90

UM-25-18

70.34

1.41

4.89

Including

70.34

0.58

6.15

UM-26-18

59.23

3.30

5.35

Including

59.23

0.28

13.20

UM-27-18

70.00

2.00

3.93

Including

70.00

0.48

11.50

UM-28-18

58.68

1.42

2.57

Including

58.68

0.21

6.34

All drill holes are vertical and intersections are considered to be close to true widths as the dip of the zone is less than 10 degrees.

Core sample analyses were undertaken by Eastern Analytical Ltd., of Springdale, Newfoundland, an ISO 17025 registered laboratory. As part of a quality control procedure a portion of the samples from the 2018 core drilling have been submitted to a second independent laboratory for check assaying. For which results are awaited.

All these drill holes were drilled in the area of the P-East Zone and were step out holes from the holes drilled in 2017 and earlier in 2018. The zinc mineralization occurs in the form of coarse grained, pale yellow to honey brown coloured sphalerite with more than 30% of the rock being sphalerite in the highest grade intervals. The balance of the rock is limestone or dolostone.

An independent Land Surveyor was engaged after the completion of all the drilling to survey the collars of all the holes drilled by Ubique in 2017 and 2018 as well as the historic holes in the area which were known to have zinc mineralization. These precise collar positions and elevations have allowed a plan and sections to be prepared which have been uploaded to the Ubique website.

The intersection in drill hole UM-25-18 is considered particularly significant as that hole and hole UM-17-18 were drilled 30 metres east of any other drilling and even though hole UM-25-18 did not intersect an extremely rich grading interval it demonstrates that more drilling is needed in it’s vicinity to locate a high grade core of the zone. Ubique President, Gerald Harper said that “he was very pleased with the results of the 2018 drilling program as they had demonstrated not only that an extension of the P Zone has been defined over a strike length of 140 metres from the limit of historic mining but that it and other zones were open ended and a drilling program in 2019 is a priority”.

More information regarding Ubique’s exploration activities and results and recently uploaded plans and sections will be found on their website at www.ubiqueminerals.com

Dr. Gerald Harper, P.Geo.(Ont), the CEO of Ubique, is the qualified person as defined by NI 43-101, responsible for the technical data presented herein and has reviewed and approved this release.

About Ubique Minerals Limited.

Ubique Minerals Limited (CSE:UBQ) is a zinc exploration company listed on the CSE (CSE:UBQ). It has focused on exploration of its 100% owned Daniel’s Harbour zinc property in Newfoundland, and was initially funded for two years by private equity including that from Greenbank Capital Inc (CSE:GBC and OTCMKTS:GRNBF and FRA:2TL). Ubique became a publicly listed company in September 2018. Ubique has undertaken one drilling program on its Daniel’s Harbour zinc project in 2017 and two more drilling campaigns in 2018, all of which were successful in delineating zinc mineralization extending from the vicinity of former mine workings. Ubique has an experienced management group with a record of multiple discoveries of deposits worldwide, and owns an extensive and exclusive database of historic exploration results from the Daniel’s Harbour area. For more information on Ubique please contact Gerald Harper, CEO, at (416) 232-9114 or by email gharper@ubiquezinc.com or see www.ubiqueminerals.com

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Ubique Minerals Limited., the raising of additional capital and the future development of the business. The forward-looking information is based on certain key expectations and assumptions made by the company’s management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Ubique can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and Ubique disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Ubique Minerals Limited

ReleaseID: 529426